Search

SAN FRANCISCO—The length of time from nephrectomy up until the diagnosis of metastatis has been confirmed as prognostic for patients whose renal cell carcinoma was treated with targeted therapies — ju

SAN FRANCISCO— Gleason score at initial diagnosis was not predictive of response to abiraterone in patients with metastatic castration-resistant prostate cancer in a pooled analysis of three trials of

SAN FRANCISCO— Four out of ten patients whose metastatic castration resistant prostate cancer had already been treated with abiraterone responded to further ‘new generation’ androgen depri

SAN FRANCISCO—A “guided missile” approach to treating metastatic, castration-resistant, taxane-refractory prostate cancer demonstrated success at the 2014 ASCO Genitourinary Cancers Sympos

SAN FRANCISCO—Orteronel — a non-steroidal selective inhibitor of 17,20-lyase — did not achieve a significant improvement in overall survival in 1099 patients randomised to treatment with this “a

NEW ORLEANS—A new oral tyrosine kinase inhibitor drug — idelalisib — has proved effective — and to have low toxicity — in patients with chronic lymphocytic leukaemia (CLL). Richard Furman MD from Weil

The rare, fatal lympho-proliferative condition: Multicentric Castleman’s Disease — MCD — could soon be treatable following findings announced at the American Society of Hematology annual meeting

LONDON— Researchers have shown that endometrial cancer — and hopefully ovarian cancer too — could potentially be detected much earlier than at present — or even prevented altogether — by looking for &

NEW ORLEANS—High remission rates with extended survival are being achieved in patients who had failed all other therapies — including allogeneic stem cell transplantation — for their acute lymphoblast

AMSTERDAM— New hopes for smokers with lung cancer were raised at the 2013 European Cancer Congress here by research findings from France, Spain and the USA using a new form of immunotherapy to treat r

AMSTERDAM— Organized screening for prostate cancer using the prostate-specific antigen (PSA) test does more harm than good, according to the findings of a French study reported here at the 2013 Europe

AMSTERDAM—Women with HER-2 positive metastatic breast cancer had significantly improved time to progression with fewer side effects after treatment with the antibody-drug conjugate T-DM1 compared to c